Portal de investigación
Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP)
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Fuster, JL
- Molinos-Quintana, A
- Velasco, P
- Pascual, T
- Rives, S
- Dapena, JL
- Sisinni, L
- Lopez-Godino, O
- Palomo, P
- Villa-Alcazar, M
- Bautista, F
- Gonzalez-Vicent, M
- Lopez-Duarte, M
- Garcia-Morin, M
- Ramos-Elbal, E
- Ramirez, M
Grupos
Abstract
Blinatumomab and inotuzumab ozogamycin represent promising alternatives to conventional chemotherapy in acute lymphoblastic leukaemia (ALL). We analysed data from 29 children with ALL treated under compassionate use with blinatumomab, inotuzumab or both. The complete remission (CR) rate in a heavily pretreated population with overt relapse was 47 center dot 6%. At earlier stages (first/second CR), both antibodies represented a useful tool to reduce minimal residual disease, and/or avoid further toxic chemotherapy until stem cell transplantation. Six patients developed grade 3 reversible non-haematological toxicity. The 12-month overall survival and event-free survival rates were 50 center dot 8 +/- 26 center dot 4% and 38 center dot 9 +/- 25 center dot 3% with blinatumomab, 45 center dot 8 +/- 26% and 27 center dot 5 +/- 25% with inotuzumab.
Datos de la publicación
- ISSN/ISSNe:
- 0007-1048, 1365-2141
- Tipo:
- Article
- Páginas:
- 764-771
- DOI:
- 10.1111/bjh.16647
- PubMed:
- 32314348
- Factor de Impacto:
- 1,907 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BRITISH JOURNAL OF HAEMATOLOGY WILEY
Citas Recibidas en Web of Science: 22
Documentos
- No hay documentos
Filiaciones
Keywords
- acute lymphoblastic leukaemia; relapse; children; blinatumomab; inotuzumab
Campos de Estudio
Cita
Fuster JL,Molinos A,FUENTES C,FERNANDEZ JM,Velasco P,Pascual T,Rives S,Dapena JL,Sisinni L,Lopez O,Palomo P,Villa M,Bautista F,Gonzalez M,Lopez M,Garcia M,Ramos E,Ramirez M. Blinatumomab and inotuzumab for B cell precursor acute lymphoblastic leukaemia in children: a retrospective study from the Leukemia Working Group of the Spanish Society of Pediatric Hematology and Oncology (SEHOP). Br. J. Haematol. 2020. 190. (5):p. 764-771. IF:6,998. (1).